Zobrazeno 1 - 10
of 288
pro vyhledávání: '"Erik R Dubberke"'
Autor:
Skye RS Fishbein, John I Robinson, Tiffany Hink, Kimberly A Reske, Erin P Newcomer, Carey-Ann D Burnham, Jeffrey P Henderson, Erik R Dubberke, Gautam Dantas
Publikováno v:
eLife, Vol 11 (2022)
Clostridioides difficile infection (CDI) imposes a substantial burden on the health care system in the United States. Understanding the biological basis for the spectrum of C. difficile-related disease manifestations is imperative to improving treatm
Externí odkaz:
https://doaj.org/article/ed671040af294f1f9d12ab8b3724ea7a
Autor:
Erik R Dubberke, Margaret A Olsen, Dustin Stwalley, Ciarán P Kelly, Dale N Gerding, Yinong Young-Xu, Cedric Mahé
Publikováno v:
PLoS ONE, Vol 11, Iss 2, p e0146822 (2016)
Population attributable risk percent (PAR%) is an epidemiological tool that provides an estimate of the percent reduction in total disease burden if that disease could be entirely eliminated among a subpopulation. As such, PAR% is used to efficiently
Externí odkaz:
https://doaj.org/article/66c5723bcd0d447bbaabfd7dbabc8cf9
Autor:
Paul Feuerstadt, Jessica R. Allegretti, Erik R. Dubberke, Amy Guo, Adam Harvey, Min Yang, Viviana Garcia-Horton, Mirko Fillbrunn, Glenn Tillotson, Lindy L. Bancke, Kerry LaPlante, Kevin W. Garey, Sahil Khanna
Publikováno v:
Infectious Diseases and Therapy, Vol 13, Iss 1, Pp 221-236 (2024)
Abstract Introduction Clostridioides difficile infection (CDI) causes symptoms of varying severity and negatively impacts patients’ health-related quality of life (HRQL). Despite antibiotic treatment, recurrence of CDI (rCDI) is common and imposes
Externí odkaz:
https://doaj.org/article/60bcb17d6e844671925f5267b451bedd
Autor:
Erin P. Newcomer, Skye R. S. Fishbein, Kailun Zhang, Tiffany Hink, Kimberly A. Reske, Candice Cass, Zainab H. Iqbal, Emily L. Struttmann, Carey-Ann D. Burnham, Erik R. Dubberke, Gautam Dantas
Publikováno v:
mBio, Vol 15, Iss 3 (2024)
ABSTRACT Clostridioides difficile infection (CDI) is a major cause of healthcare-associated diarrhea, despite the widespread implementation of contact precautions for patients with CDI. Here, we investigate strain contamination in a hospital setting
Externí odkaz:
https://doaj.org/article/5b0d6137a6d94808a3f8cb45d14b3fc9
Autor:
Jonathan D. Baghdadi, Mia Wessel, Erik R. Dubberke, Alison Lydecker, Kimberly C. Claeys, Carolyn Alonso, K.C. Coffey, Michael Durkin, Anne J. Gonzales-Luna, Alice Y. Guh, Jennie H. Kwon, Elise Martin, Preeti Mehrotra, Christopher R. Polage, Michael S. Pulia, Clare Rock, Andrew M. Skinner, Valerie M. Vaughn, Tara Vijayan, Michael E. Yarrington, Daniel J. Morgan, for the CDC Prevention Epicenters Program
Publikováno v:
Antimicrobial Stewardship & Healthcare Epidemiology, Vol 4 (2024)
Abstract Background: Clostridioides difficile infection (CDI) may be misdiagnosed if testing is performed in the absence of signs or symptoms of disease. This study sought to support appropriate testing by estimating the impact of signs, symptoms, a
Externí odkaz:
https://doaj.org/article/546f64248cc848398d91942e1934cbff
Publikováno v:
Infectious Diseases and Therapy, Vol 12, Iss 2, Pp 703-709 (2022)
Abstract Introduction Effective treatments for recurrent Clostridioides difficile infection (rCDI) are urgently needed. RBX2660 is an investigational microbiota-based live biotherapeutic to reduce CDI recurrence following standard-of-care antibiotic
Externí odkaz:
https://doaj.org/article/2e7f50ec5e7e4df399a1afc1eec29479
Autor:
Nicole J. Tarlton, Meghan A. Wallace, Robert F. Potter, Kailun Zhang, Gautam Dantas, Erik R. Dubberke, Carey-Ann D. Burnham, Melanie L. Yarbrough
Publikováno v:
Microbiology Spectrum, Vol 11, Iss 3 (2023)
ABSTRACT An isolate of Morganella morganii (MMOR1) that tested susceptible to 3rd/4th-generation cephalosporins and intermediate to meropenem was characterized as positive for NDM and IMP carbapenemases by NG-Test CARBA 5. Our objective was to furthe
Externí odkaz:
https://doaj.org/article/a9c4edea86ff4ef89dede3824613d27b
Autor:
Christine Lee, Thomas Louie, Lindy Bancke, Beth Guthmueller, Adam Harvey, Paul Feuerstadt, Sahil Khanna, Robert Orenstein, Erik R. Dubberke
Publikováno v:
Therapeutic Advances in Gastroenterology, Vol 16 (2023)
Background: Microbiota-based treatments reduce the incidence of recurrent Clostridioides difficile infections (rCDIs), but prospectively collected safety data needed to broaden patient access and protect public health have been limited. Objectives: W
Externí odkaz:
https://doaj.org/article/8cc4ae3fc160414a878b1f6287d6adf4
Autor:
Josephine Fox, Ashley Rumsey, Rebecca Rojek, Kathleen Rensing, Heather Gasama, Lydia Grimes-Jenkins, Helen Wood, Erik R. Dubberke, David K. Warren
Publikováno v:
Infection Prevention in Practice, Vol 5, Iss 1, Pp 100268- (2023)
Summary: Prevention of hazardous drug exposure is essential in averting unnecessary health risks to health care workers (HCW). To address the risk to HCWs when handling hazardous drugs, engineering controls can be utilized to reduce the exposure. A c
Externí odkaz:
https://doaj.org/article/e4785839bcaf4a4e89d30c2520d3aab4
Autor:
Robert Orenstein, Erik R. Dubberke, Sahil Khanna, Christine H. Lee, David Yoho, Stuart Johnson, Gail Hecht, Herbert L. DuPont, Dale N. Gerding, Ken F. Blount, Sarah Mische, Adam Harvey
Publikováno v:
BMC Infectious Diseases, Vol 22, Iss 1, Pp 1-13 (2022)
Abstract Background Effective treatment options for recurrent Clostridioides difficile infection (rCDI) are limited, with high recurrence rates associated with the current standard of care. Herein we report results from an open-label Phase 2 trial to
Externí odkaz:
https://doaj.org/article/2b6ddb482f4647ea80752eeb69327c09